What will I learn?

The programme strategy is to drive research for the benefit of patients affected by cancer and by inherited disease in Wales and beyond. The programme of research maps onto the translational research pathway ranging from fundamental science through to pre-clinical testing of new therapeutic agents as well as early and late phase clinical trials. Our translational research focuses on the genetic and molecular basis of human disease within a central theme of cancer. The Division of Cancer and Genetics provides expertise and facilities to conduct research into human genetics and disease, prognostic and diagnostic markers for cancer, novel therapies for solid organ and haematological cancers, metastasis, cancer immunology and cancer cell biology. Translational research encompassing fundamental biology, applied and clinical research is undertaken in all areas of research. The translational loop is closed by aiming to provide new diagnostics for cancer risk and new cancer therapeutics by facilitating the partnerships between Patient, Scientist, Clinician and Pharma Industries.

The areas studied include genome instability (telomere-driven genome instability and DNA damage and repair), the molecular genetics of cancer and inherited tumour predisposition including tuberous sclerosis and Rett syndrome.

The programme will lead to a research degree in cancer and / or genetics that could be used in a variety of academic, clinical and industrial settings. The following areas are available: Haematological malignancy - focus on basic and translational research into haematological malignancies and clinical trials exploring innovative treatment for leukaemia; Genetic and genomic medicine - to better understand the underlying mechanisms of cancer and genetic illness; Solid cancers - aiming to improve the outcome of patients with cancer with a primary focus on clinical trials and linked laboratory research. The underlying science is multidisciplinary including imaging, cell and molecular biology as well cross-cutting themes with immunology and pharmacy. In all cases, designing and delivering multi-centre late-phase clinical trials and associated translational research in various solid cancers and haematological malignancies is a significant area of research within the Division. Here the development of therapies designed for specific individuals with specific cancers is an objective.

Which department am I in?

School of Medicine

Study options

Full Time (4 years)

Tuition fees
To be confirmed

*Price shown is for indicative purposes, please check with institution

Start date

September 2019

Venue

Cardiff University

PO Box 921,

Cardiff,

CF10 3XQ, Wales

Entry requirements

For international students

Students need to have either: IELTS (Academic) 6.5 (with at least 5.5 in each sub-score); at least 90 with minimum scores of 17 for writing, 17 for listening, 18 for reading and 20 for speaking in Test of English as Foreign Language (TOEFL) iBT; 62 with a minimum of 51 in all communicative skills in Pearson Test of English (Academic); successful completion of ISE III with a ‘pass’ in all four components or IELTS (Academic) 7.0 overall and no less than 6.0 in each sub-score; at least 100 with minimum scores of 24 for writing, 22 for listening, 24 for reading and 25 for speaking in Test of English as Foreign Language (TOEFL) iBT; 70 with no less than 54 in all skills in Pearson Test of English (Academic); successful completion of ISE III with at least a Merit in all components.

Find your nearest IELTS test centre and test dates

There may be different IELTS requirements depending on your chosen course.

ADD TO MY FAVOURITES

About this uni

Cardiff University is recognised by international employers from the globe-over, making its graduates highly sought after.

  • Ranked in the world’s top 100
  • Based in one of the safest capital cities in Europe
  • High quality teaching with highly qualified teaching staff
  • Recently invested GBP600m in its facilities